

ONCOLOGY PORTFOLIO - Approved Products & Pipeline

INN /COMPOUND	CLASS	TARGET & MODALITY	INDICATION OR DISEASE	Discovery	Preclinical	Phase I	Phase II	Phase III	In Registration	Approved*	
Vinorelbine	Chemotherapy	Vinca Alkaloid	Advanced BREAST CANCER as monotherapy or in combination with other agents								
		Vinca Alkaloid	Advanced NSCLC as monotherapy or in combination with other chemotherapies								
		Vinca Alkaloid	Adjuvant treatment of NSCLC in combination with platinum-based chemotherapy								
Vinflunine	Chemotherapy	Vinca Alkaloid	Advanced or metastatic transitional-cell carcinoma of the UROTHELIAL tract								
Neratinib ¹	Targeted therapy	Pan-HER inhibitor	HER2 amplified / overexpressed / HR+ early BREAST CANCER (extended adjuvant post trastuzumab based therapy)								
Tabelecleucel ²	Cell therapy	Allogeneic T-cell immunotherapy	Epstein-Barr virus associated post-transplant lymphoproliferative disease (EBV + PTLD)								
Encorafenib ³ / Binimetinib ⁴ (± other agents)	Targeted therapy	BRAF inhibitor + MEK inhibitor	Unresectable or metastatic <i>BRAF</i> ^{V600} -mutant MELANOMA								
		BRAF inhibitor + MEK inhibitor	Metastatic <i>BRAF</i> ^{V600E} -mutant NSCLC ⁵								
		BRAF inhibitor	Metastatic <i>BRAF</i> ^{V600E} -mutant CRC after prior systemic therapy								
		BRAF inhibitor	Metastatic <i>BRAF</i> ^{V600E} -mutant CRC in first-line treatment ⁵								
		BRAF inhibitor + MEK inhibitor	Metastatic <i>BRAF</i> ^{V600E} -mutant NSCLC in Chinese population - OCEAN study								
Exarafenib ⁶	Targeted therapy	Pan-RAF small molecule inhibitor	<i>NRAS</i> mutant MELANOMA and other <i>BRAF</i> / <i>NRAS</i> mutant solid tumors								
PFL-721 ⁷	Targeted therapy	Mutant-selective EGFR-exon 20 small molecule inhibitor	NSCLC with <i>EGFR</i> exon 20 insertion mutation								
PFL-241 ⁷	Targeted therapy	Mutant-selective 4 th generation EGFR small molecule inhibitor	NSCLC with <i>EGFR</i> exon 19/21 + C797S mutations								
PFL-002 ⁸	Targeted therapy	Anti-cMET antibody degrader	NSCLC / solid tumors with mutations or amplification of <i>MET</i>								
Not-disclosed ⁹	Targeted therapy	Multiple targets	ONCOLOGY								

*Approved at least by EMA. Vinorelbine was approved by National Health Authorities (before EU centralized procedure implementation).

1.Commercialized in partnership with Puma Biotechnology. 2.Commercialized in partnership with Atara Biotherapeutics. 3.Encorafenib + cetuximab is approved for *BRAF*^{V600E}-mutant mCRC, after prior systemic therapy. Encorafenib + binimetinib is approved for unresectable or metastatic *BRAF*-mutant melanoma, in adult patients. 4.Developed and launched in partnership with Array Biopharma (partnered with Pfizer since 2020). 5.Clinical development under Pfizer sponsorship. 6.Originated by Kinnate Biopharma Inc. Investigational Pan-RAF inhibitor, Exarafenib, acquired by Pierre Fabre Laboratories. 7.Originated by Scorpion Therapeutics acquired by Pierre Fabre Laboratories. 8.Originated by Vertical Bio AG, acquired by Pierre Fabre Laboratories. 9.Discovery partnership with Vernalis Lt and RedRidge Bio.

This display includes ongoing clinical trials for both approved and investigational compounds. Inclusion in this display does not imply regulatory approval for these compounds or all indications. Products should be used in accordance with their prescribing information. Information about the trials can be found at www.ClinicalTrials.gov

HQ--03-24-2400065 - V10 - Elaboration date: December 2025



LABORATOIRES
Pierre Fabre